In this article, we will be taking a look at the 10 Best Beaten Down Stocks to Invest in According to Analysts.
When markets start to mistake short-term losses for long-term declines, oversold equities frequently get fresh attention. This is the point at which insider purchasing becomes especially significant. Executives at the company usually have a better understanding of whether a slump is an overreaction or a true business issue. Insider purchases may indicate a leadership opportunity where the market perceives risk, even though a stock may continue to be inexpensive for legitimate reasons.
This viewpoint is consistent with institutional tactics. The Undiscovered Managers Behavioral Value Fund, according to J.P. Morgan Asset Management, seeks to “capitalize on behavioral biases” by identifying businesses that have excellent fundamentals, indications of market overreaction, and substantial insider buying or stock repurchases. Franklin Templeton, who notes that unusual insider action might lead to a reevaluation of a stock’s prospects, also stresses investing in companies with sound balance sheets that trade below their true value. When taken as a whole, these strategies highlight insider conduct as a crucial sign when sentiment propels steep selloffs.
The overall market environment is still favorable going forward. Morgan Stanley Investment Management’s Andrew Slimmon presented his 2026 outlook on January 22. He predicted more gains due to expected rate decreases and positive sentiment driven by artificial intelligence. While short-term concern may be caused by volatility related to the U.S. midterm elections, optimism is anticipated to be sustained by rising consumer mood and the residual impacts of the Fed’s 2025 rate decreases.
This momentum is expected to be led by technology in particular. On February 2, Forrester projected that U.S. technology spending will rise by 8.3% to around $2.9 trillion by 2026. The concept that technology stocks, especially those under pressure in 2025, could benefit from both long-term structural growth and increasing mood is supported by this prognosis.
With that said, let’s look at the best 52-week low stocks.
Stocks
Our Methodology
For our methodology, we screened for stocks with an RSI below 30 and a positive upside of at least 20%. From this list, we selected the top 10 stocks with recent news and developments and ranked them in ascending order based on their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Here is our list of the 10 best beaten-down stocks to invest in, according to analysts.
10. T-Mobile US, Inc. (NASDAQ:TMUS)
Price Target Upside: 38.23%
T-Mobile US, Inc. (NASDAQ:TMUS) is one of the best 52-week low stocks.
TheFly reported on April 13 that KeyBanc Capital Markets analyst Brandon Nispel lifted TMUS from Sector Weight to Overweight and set a $260 price objective, citing stronger organic EBITDA momentum, additional growth drivers, a favorable wireless fixed broadband position, a solid balance sheet that allows strategic flexibility, and a valuation that appears low compared with its historical range, with upcoming quarterly results viewed as a potential positive trigger.
Additionally, on April 7, Mint Mobile, a subsidiary of T-Mobile US, Inc., introduced its “Unf*! Your Bills” bundle on April 7, 2026. which combines one year of 5G home internet service branded as MINTernet with unlimited premium wireless access for $45 per month. According to the company, the offer targets consumers frustrated with complex cable pricing structures, extra charges, and restrictive contracts by providing a simpler, lower-cost alternative.
Marketing emphasizes that the plan removes common billing surprises and consolidates services into a single monthly payment intended to improve transparency and affordability compared with traditional providers. It positions Mint Mobile as a challenger brand seeking to simplify connectivity while offering bundled home internet and mobile service under one predictable price point in the market.
T-Mobile US, Inc. is a major wireless telecommunications provider in the United States, offering mobile voice, messaging, and data services. It is known for its nationwide 5G network and competitive pricing strategy in the wireless industry.
9. The Simply Good Foods Company (NASDAQ:SMPL)
Price Target Upside: 39.51%
The Simply Good Foods Company (NASDAQ:SMPL) is one of the best 52-week low stocks on this list.
TheFly reported on April 10 that Stephens lowered SMPL from Overweight to Equal Weight and reduced its price target from $24 to $14 after a weak second-quarter performance and a sharp cut in forward guidance. The firm pointed to broad softness in demand across the brand lineup, with declining distribution, weaker product movement at retail, and disappointing results from new offerings. It also noted that recent investor discussions suggest reduced enthusiasm for turnaround-driven stories, especially within smaller consumer packaged food companies, where recovery expectations are now more limited.
Additionally, on April 9, The Simply Good Foods Company revised its fiscal 2026 outlook alongside its second-quarter earnings release. The company now expects net sales between $1.31 billion and $1.35 billion, reflecting a year-over-year decline of 10% to 7%. Gross margin is projected to contract by 300 to 350 basis points, while adjusted EBITDA is guided between $217 million and $225 million, representing a 22% to 19% decrease.
For the third quarter, the company forecasts revenue of $329 million to $338 million and adjusted EBITDA of $46 million to $50 million. The updated guidance reflects ongoing weakness in demand, margin pressure from higher input costs, and continued softness across key brands, including Atkins and OWYN.
The Simply Good Foods Company is a consumer packaged food company that develops and markets nutritional snacking products. Its portfolio includes protein bars, shakes, and snacks focused on health-conscious consumers and active lifestyles.
8. CoStar Group, Inc. (NASDAQ:CSGP)
Price Target Upside: 69.99%
CoStar Group, Inc. (NASDAQ:CSGP) is among the best 52-week low stocks to invest in.
TheFly reported on April 13 that Robert W. Baird CSGP reduced its price target to $56 from $73 while maintaining an Outperform rating. The firm adjusted its valuation model after reports indicated that Third Point had withdrawn its interest in the company and would not move forward with a proxy contest.
Moreover, Reuters reported on April 12 that billionaire Daniel Loeb’s hedge fund, Third Point, has abandoned plans to initiate a proxy battle against CoStar Group, Inc. and has fully exited its investment in the company. The decision followed a reassessment of its earlier strategy to push CoStar toward prioritizing its core operations, which the firm concluded would not produce the expected recovery.
According to sources and investor communication, the fund determined that its original investment thesis was no longer valid under current conditions. As a result, Third Point chose to divest its entire position and step away from any activist involvement, signaling a notable change in stance after previously considering measures to influence the company’s direction and operational focus.
CoStar Group, Inc. is a leading provider of commercial real estate information, analytics, and online marketplaces. It offers data-driven platforms that help investors, brokers, and businesses make informed property and market decisions.
7. Wix.com Ltd. (NASDAQ:WIX)
Price Target Upside: 77.09%
Wix.com Ltd. (NASDAQ:WIX) is among the best 52-week low stocks.
TheFly reported on April 9 that Barclays lowered its price target on WIX to $155 from $160 while maintaining an Overweight rating. The firm noted an uneven outlook for web tools companies heading into first-quarter earnings, highlighting the importance of stronger bookings growth and the company’s ability to sustain its full-year free cash flow margin expectations.
Separately, a day earlier, on April 8, TikTok introduced a global integration with Wix.com Ltd. aimed at connecting online storefronts directly with its advertising and discovery ecosystem. The integration enables businesses to link their WIX websites with TikTok for Business, allowing them to create, manage, and refine marketing campaigns within a unified system. It supports the setup of key performance tools such as tracking pixels, event-based data sharing, and product catalogs, helping businesses build a more data-driven marketing approach.
By aligning website infrastructure with TikTok’s content-driven platform, the integration is designed to streamline how brands attract users and convert engagement into transactions. The collaboration focuses on reducing friction between audience discovery and purchasing activity, while giving businesses the ability to scale campaigns more efficiently and reach new customer segments through a single connected environment.
Wix.com Ltd. is a cloud-based platform that enables users to create and manage websites through drag-and-drop tools. It offers hosting, design, e-commerce, and business solutions for individuals and small businesses to build an online presence.
6. Insulet Corporation (NASDAQ:PODD)
Price Target Upside: 81.99%
Insulet Corporation (NASDAQ:PODD) is among the best 52-week low stocks to invest in.
TheFly reported on April 7 that Citigroup lowered PODD from Buy to Neutral and reduced its price target to $230 from $338 ahead of the company’s first-quarter results. The downgrade was driven by concerns over rising competition in the patch pump market. The firm also indicated that upcoming rival devices expected to enter the market in 2027 could limit the stock’s ability to outperform going forward.
Additionally, on March 30, Insulet Corporation appointed Mike Panos as Executive Vice President and Chief Commercial Officer, effective immediately. In this role, he will oversee the company’s global commercial operations and report directly to President and CEO Ashley McEvoy, while also joining the executive leadership team. The company highlighted that the appointment supports its strategy to expand adoption of its Omnipod platform and strengthen execution across international markets. Management emphasized growth opportunities driven by clinical performance, patient-focused innovation, and broader use of automated insulin delivery in both type 1 and type 2 diabetes.
Panos brings around 30 years of experience in medical technology sales leadership, including senior roles at Stryker Corporation, such as leading major divisions and overseeing North American and global commercial functions. His background includes building large-scale sales organizations, expanding market reach, and driving consistent revenue growth. PODD expects his expertise to enhance commercial discipline, support expansion into new patient groups, and accelerate overall global growth initiatives.
Insulet Corporation is a medical device company focused on insulin delivery systems for people with diabetes. It is best known for its Omnipod tubeless insulin pump, which provides continuous insulin therapy through a wearable, automated system designed to simplify diabetes management.
5. FitLife Brands, Inc. (NASDAQ:FTLF)
Price Target Upside: 97.07%
FitLife Brands, Inc. (NASDAQ:FTLF) is one of the best 52-week low stocks on our list.
TheFly reported on April 6 that Roth Capital reduced its price target on FTLF to $17 from $25 while maintaining a Buy rating after the company reported weaker-than-expected fourth-quarter results. The firm attributed the earnings decline to slowing demand in certain online product lines, elevated protein input costs, and the discontinuation of CBD-related offerings. It also noted that while select core products continue to perform well, other segments that began losing momentum in the third quarter extended their slowdown into the fourth quarter.
In addition to that, it was reported on April 1 that FitLife Brands, Inc. reported fourth-quarter fiscal 2025 revenue of $25.9 million, compared with $15 million in the same period last year. Management noted that most brand groups delivered strong performance during 2025, except MRC, which saw a 15% revenue decline over the year. Excluding MRC and MusclePharm, legacy FitLife brands generated about 6% organic growth. MusclePharm also contributed with 5% organic growth across both online and wholesale channels. Additionally, Irwin, in its first full quarter under ownership, recorded 6% organic growth. Overall, the results reflected broad-based expansion across key segments despite weakness in one brand category.
FitLife Brands, Inc. is a consumer health and wellness company that develops and markets nutritional supplements and lifestyle products. Its brands focus on fitness, weight management, and active living.
4. Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Price Target Upside: 109.46%
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the best 52-week low stocks on our list.
TheFly reported on April 13 that Evercore ISI reduced its price target on VRDN to $24 from $32 while maintaining an Outperform rating ahead of the company’s first-quarter earnings update. The adjustment reflects a revised outlook incorporated into the firm’s preview of upcoming results.
In other news, it was reported earlier on April 6 that Shares of Viridian Therapeutics, Inc. declined sharply after Amgen reported positive Phase 3 results for Tepezza delivered via subcutaneous injection using an on-body device in patients with moderate to severe active thyroid eye disease. The results included achievement of both primary and secondary endpoints, increasing competitive pressure in the same treatment area where Viridian is also developing a therapy for thyroid eye disease.
Following the announcement, VRDN’s stock dropped approximately 19%, or $3.61, trading around $15.23 in morning activity. The move reflected investor concern that the new clinical data from a competing program could impact Viridian’s future commercial positioning and market expectations within the TED treatment landscape, particularly as both companies target overlapping patient populations and indications.
Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious rare diseases. It is primarily targeting thyroid eye disease with innovative biologic treatments designed to improve patient outcomes and reduce disease burden.
3. Byrna Technologies Inc. (NASDAQ:BYRN)
Price Target Upside: 175.23%
Byrna Technologies Inc. (NASDAQ:BYRN) is among the best 52-week low stocks to invest in.
TheFly reported on April 10 that Craig-Hallum downgraded BYRN from Buy to Hold and set a $7.50 price target, citing recent operational instability and leadership changes. The firm pointed to a new CEO appointment, along with a sharp decline in online conversion rates over the past two months, as key factors behind the weaker outlook. It noted that management is attempting to expand the customer base and rebuild marketing efforts, but expects these initiatives to require time and additional spending, which could weigh on profitability. Craig-Hallum also stated that current market expectations appear too high and suggested the shares may remain under pressure until consistent performance improvements justify a higher valuation.
Previously, on April 9, Byrna Technologies Inc. reported fiscal first-quarter 2026 results showing net revenue of $29.0 million, up from $26.2 million in the prior-year period, reflecting continued expansion across dealer and retail chain channels. Gross profit rose to $17.4 million, although gross margin slightly declined due to a higher mix of dealer and chain store sales.
The corporation’s Operating expenses increased to $16.5 million, driven mainly by higher advertising, marketing, legal, and professional costs supporting distribution growth and brand awareness efforts. Net income was $0.8 million compared with $1.7 million a year earlier, while adjusted EBITDA totaled $2.2 million versus $3.0 million. The company also reported $9.6 million in cash and securities and noted ongoing efforts to improve working capital efficiency and reduce inventory levels over time.
Byrna Technologies Inc. is a defense technology company that designs and manufactures non-lethal personal security products. Its portfolio includes CO2-powered launchers and projectiles intended for civilian, law enforcement, and security use as alternatives to firearms.
2. Forum Markets, Incorporated (NASDAQ:FRMM)
Price Target Upside: 179.33%
Forum Markets, Incorporated (NASDAQ:FRMM) is one of the best beaten-down stocks on this list.
TheFly reported on April 7 that Benchmark initiated coverage on FRMM with a Speculative Buy rating and a $5 price target. The firm highlighted the company’s strategic shift toward institutional-grade real-world asset tokenization built on Ethereum layer-2 networks, describing it as part of a broader transformation in global capital markets. It emphasized that Forum Markets has rapidly repositioned itself within this emerging segment and is aligned with expected expansion in tokenized asset adoption.
Separately, on April 8, Forum Markets, Incorporated announced a new capital deployment initiative focused on providing short-term bridge loans for the acquisition and rollout of NVIDIA AI chips used in data center infrastructure. The arrangement involves financing hardware purchases before permanent funding becomes available, once projects become operational and revenue-generating. These loans are structured as short-duration instruments, typically repaid within 60 to 120 days through takeout financing from institutional lenders after deployment.
The business targets annualized returns in the mid-teens from its initial commitments and expects the strategy to enhance its broader tokenization platform. Forum also noted that it may tokenize portions of these investments, allowing AI infrastructure credit exposure to be distributed through its digital asset ecosystem. The initiative is designed to expand capital deployment opportunities while supporting rapidly growing demand for AI compute infrastructure.
Forum Markets, Incorporated develops platforms that enable the conversion of illiquid, institutional-grade assets into blockchain-based financial instruments using Ethereum Layer 2 protocols.
1. BioXcel Therapeutics, Inc. (NASDAQ:BTAI)
Price Target Upside: 1,076.47%
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is one of the best 52-week low stocks.
TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating. The firm attributed the revision to concerns over recent and expected equity dilution, which influenced its updated valuation outlook.
Separately, on April 8, BioXcel Therapeutics, Inc. announced that it has begun enrolling the first patients in a U.S. Department of War-funded Phase 2a clinical study evaluating BXCL501 for acute stress reactions. The trial is being conducted in collaboration with the University of North Carolina at Chapel Hill Institute of Trauma Recovery and is designed as a randomized, placebo-controlled study enrolling around 100 participants who experience trauma-related acute stress, such as after motor vehicle accidents.
The research will assess whether BXCL501 can reduce symptom severity, improve cognitive functioning, and help prevent progression to longer-term neuropsychiatric conditions like post-traumatic stress disorder. The medication is being supplied by the company for the study. Acute stress reactions are common in both civilian and military populations and represent a large unmet medical need. The trial represents a key step in expanding clinical research for BXCL501 in trauma-related psychiatric indications and advancing potential pharmacological treatment options.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses artificial intelligence to identify and develop new therapies. It focuses on neuroscience and immuno-oncology, advancing treatments for conditions such as agitation, schizophrenia, and cancer.
READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.
Hedge Fund Resource Center